Breaking News

Adimab Expands Collaborations with Merck and Lilly

January 8, 2013

Adimab has expanded its research collaborations with Merck and Lilly. The new agreement provides Merck with expanded access to its technology to identify human antibody candidates, including potentially bispecific antibody candidates across all disease areas. Adimab will discover therapeutic antibody candidates to multiple targets selected by Merck for a three-year period. Adimab will receive upfront payments and is eligible to receive preclinical and clinical development milestones, as well as royalties on product sales.
 
Additionally, Adimab has expanded its research agreement with Lilly to include the discovery and optimization of multiple bispecific antibodies targeting molecular targets identified by Lilly.
 
“We are always pleased when our existing partners choose to expand their relationship with us,” said Tillman Gerngross, Adimab’s chief executive officer and co-founder. “The antibody discovery arena has become very competitive and nothing is more validating than existing partners coming back for broader access to our platform.”

Related Contract Manufacturing:

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research